Long-term efficacy and safety of human papillomavirus vaccination

References

• WalboomersJMJacobsMVManosMMHuman papillomavirus is a necessary cause of invasive cervical cancer worldwideJ Pathol19991891121910451482
   PubMed Web of Science ®Google Scholar
• de SanjoseSQuintWGAlemanyLHuman papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyLancet Oncol201011111048105620952254
   PubMed Web of Science ®Google Scholar
• BoschFXBurchellANSchiffmanMEpidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasiaVaccine200826Suppl 10K1K1618847553
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFChapter 2: The burden of HPV-related cancersVaccine200624Suppl 3S3/112516949997
   PubMed Web of Science ®Google Scholar
• SchillerJTCastellsaguéXGarlandSMA review of clinical trials of human papillomavirus prophylactic vaccinesVaccine201230Suppl 5F123F13823199956
   PubMed Web of Science ®Google Scholar
• KirnbauerRBooyFChengNLowyDRSchillerJTPapillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenicProc Natl Acad Sci U S A1992892412180121841334560
   PubMed Web of Science ®Google Scholar
• StanleyMHPV – immune response to infection and vaccinationInfect Agent Cancer201051920961432
   PubMedGoogle Scholar
• GarlandSMHernandez-AvilaMWheelerCMQuadrivalent vaccine against human papillomavirus to prevent anogenital diseasesN Engl J Med2007356191928194317494926
   PubMed Web of Science ®Google Scholar
• FUTURE II Study GroupQuadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesionsN Engl J Med2007356191915192717494925
   PubMed Web of Science ®Google Scholar
• PaavonenJJenkinsDBoschFXEfficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialLancet200736995802161217017602732
   PubMed Web of Science ®Google Scholar
• HerreroRHildesheimARodríguezACRationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaVaccine200826374795480818640170
   PubMed Web of Science ®Google Scholar
• MuñozNKjaerSKSigurdssonKImpact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young womenJ Natl Cancer Inst2010102532533920139221
   PubMed Web of Science ®Google Scholar
• LehtinenMPaavonenJWheelerCMOverall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialLancet Oncol2012131899922075171
   PubMed Web of Science ®Google Scholar
• De VincenzoRRicciCConteCScambiaGHPV vaccine cross-protection: highlights on additional clinical benefitGynecol Oncol20131303642651 Review23747835
   PubMed Web of Science ®Google Scholar
• IwasakiAMedzhitovRToll-like receptor control of the adaptive immune responsesNat Immunol200451098799515454922
   PubMed Web of Science ®Google Scholar
• BrownDRGarlandSMFerrisDGThe humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassayHum Vaccin20117223023821307649
   PubMed Web of Science ®Google Scholar
• EinsteinMHBaronMLevinMJComparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHum Vaccin200951070571919684472
   PubMed Web of Science ®Google Scholar
• EinsteinMHBaronMLevinMJComparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 yearsHum Vaccin20117121343135822048173
   PubMed Web of Science ®Google Scholar
• StanleyMPotential mechanisms for HPV vaccine-induced long-term protectionGynec Oncol2010118Suppl 1S2S720494220
   PubMedGoogle Scholar
• KreimerARRodriguezACHildesheimAProof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineJ Natl Cancer Inst2011103191444145121908768
   PubMed Web of Science ®Google Scholar
• DobsonSRMcNeilSDionneMImmunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialJAMA2013309171793180223632723
   PubMed Web of Science ®Google Scholar
• KrajdenMCookDYuAAssessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trialVaccine201432562463024055350
   PubMed Web of Science ®Google Scholar
• WardSMPhaloraPBradshawDLeyendeckersHKlenermanPDirect ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virusJ Infect Dis2008198681381718662131
   PubMed Web of Science ®Google Scholar
• OlssonSEVillaLLCostaRLInduction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine200725264931493917499406
   PubMed Web of Science ®Google Scholar
• Rowhani-RahbarAMaoCHughesJPLonger term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccineVaccine200927415612561919647066
   PubMed Web of Science ®Google Scholar
• Rowhani-RahbarAAlvarezFBBryanJTEvidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccineJ Clin Virol201253323924322209292
   PubMed Web of Science ®Google Scholar
• MoscickiABWheelerCMRomanowskiBImmune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult womenVaccine201231123424123063422
   PubMed Web of Science ®Google Scholar
• VillaLLAultKAGiulianoARImmunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18Vaccine20062427–285571558316753240
   PubMed Web of Science ®Google Scholar
• NygårdMKrüger KjaerSDillnerJLong-term effectiveness and immunogenicity of Gardasil™ in the Nordic countriesPoster presented at: Eurogin 2013: HPV at a Crossroads – 30 Years of Research and PracticeNovember 3–6, 2013Florence, Italy
   Google Scholar
• RanaMMHuhtalaHApterDUnderstanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-upInt J Cancer2013132122833283823180157
   PubMed Web of Science ®Google Scholar
• ReisingerKSBlockSLLazcano-PonceESafety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialPediatr Infect Dis J200726320120917484215
   PubMed Web of Science ®Google Scholar
• IversenOELong-term extension study of Gardasil in adolescents: results through month 96Poster presented at: Eurogin 2013: HPV at a Crossroads – 30 Years of Research and PracticeNovember 3–6, 2013Florence, Italy
   Google Scholar
• MuñozNManalastasRJrPitisuttithumPSafety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trialLancet200937396791949195719493565
   PubMed Web of Science ®Google Scholar
• CastellsaguéXMuñozNPitisuttithumPEnd-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBr J Cancer20111051283721629249
   PubMed Web of Science ®Google Scholar
• LunaJPlataMGonzalezMLong-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult womenPLoS One2013812e8343124391768
   PubMed Web of Science ®Google Scholar
• GiulianoARPalefskyJMGoldstoneSEfficacy of quadrivalent HPV vaccine against HPV infection and disease in malesN Engl J Med2011364540141121288094
   PubMed Web of Science ®Google Scholar
• PalefskyJMGiulianoARGoldstoneSHPV vaccine against anal HPV infection and anal intraepithelial neoplasiaN Engl J Med2011365171576158522029979
   PubMed Web of Science ®Google Scholar
• HuangLMSchwarzTFValenciaALong-term immunogenicity and safety of the HPV-16/18 as04-adjuvanted vaccine in adolescent girls aged 10–14 years: 7-year follow-upPoster presented at: Eurogin 2013: HPV at a Crossroads – 30 Years of Research and PracticeNovember 3–6, 2013Florence, Italy
   Google Scholar
• HarperDMFrancoELSWheelerCEfficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialLancet200436494471757176515541448
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Vaccine HPV-007 Study GroupRomanowskiBde BorbaPCSustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 yearsLancet200937497061975198519962185
   PubMed Web of Science ®Google Scholar
• Roteli-MartinsCMNaudPSDe BorbaPSustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-upHum Vaccin Immunother20128339039722327492
   PubMed Web of Science ®Google Scholar
• NaudPSRoteli-MartinsCMDe CarvalhoNSSustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccinationHum Vaccin Immunother2014108
   Web of Science ®Google Scholar
• SchwarzTFSpaczynskiMSchneiderAPersistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 yearsHum Vaccin20117995896521892005
   PubMed Web of Science ®Google Scholar
• SchwarzTFSpaczynskiMWysockiJPersistence of immune response 7 years after administration of the HPV-16/18 as04-adjuvanted vaccine to women aged 15–55 yearsPoster presented at: Eurogin 2013: HPV at a Crossroads – 30 Years of Research and PracticeNovember 3–6, 2013Florence, Italy
   Google Scholar
• PetäjäTKeränenHKarppaTImmunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 yearsJ Adolesc Health2009441334019101456
   PubMed Web of Science ®Google Scholar
• PedersenCPetajaTStraussGImmunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvantJ Adolesc Health200740656457117531764
   PubMed Web of Science ®Google Scholar
• LuBKumarACastellsaguéXGiulianoAREfficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysisBMC Infect Dis2011111321226933
   PubMed Web of Science ®Google Scholar
• KangSKimKHKimYTSafety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjectsInt J Gynecol Cancer2008181013101917986242
   PubMed Web of Science ®Google Scholar
• GonçalvesAKCobucciRNRodriguesHMde MeloAGGiraldoPCSafety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative reviewBraz J Infect Dis Epub4272014
   Web of Science ®Google Scholar
• WacholderSChenBEWilcoxARisk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trialsBMJ2010340c71220197322
   PubMed Web of Science ®Google Scholar
• BergmanSJCollins-LuceyEUpdate on human papillomavirus vaccines: life saver or controversy magnet?Clin Microbiol Newsl201234118591
   Google Scholar
• JuniorGMHuman papillomavirus vaccine: use in pregnancy and malformation riskRev Bras Patol Trato Genit Infer201228182
   Google Scholar
• GarlandSMAultKAGallSAPregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trialsObstet Gynecol200911461179118819935017
   PubMed Web of Science ®Google Scholar
• DanaABuchananKMGossMAPregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccineObstet Gynecol200911461170117819935016
   PubMed Web of Science ®Google Scholar
• SladeBALeidelLVellozziCPostlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccineJAMA2009302775075719690307
   PubMed Web of Science ®Google Scholar
• FranceschiniSAHuman papillomavirus vaccine use in menRev Bras Patol Trato Genit Infer201229296
   Google Scholar
• Centers for Disease Control and Prevention (CDC)Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013 – United StatesMMWR Morb Mortal Wkly Rep2013622959159523884346
   PubMed Web of Science ®Google Scholar
• AngeloMGDavidMPZimaJPooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmePharmacoepidemiol Drug Saf201423546647924644063
   PubMed Web of Science ®Google Scholar
• DescampsDHardtKSpiessensBSafety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer preventionHum Vaccin20095533234019221517
   PubMed Web of Science ®Google Scholar
• GeeJNalewayAShuiIMonitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety DatalinkVaccine201129468279828421907257
   PubMed Web of Science ®Google Scholar
• ChaoCKleinNPVelicerCMSurveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccineJ Intern Med2012271219320321973261
   PubMed Web of Science ®Google Scholar
• KleinNPHansenJChaoCSafety of quadrivalent human papillomavirus vaccine administered routinely to femalesArch Pediatr Adolesc Med2012166121140114823027469
   PubMed Web of Science ®Google Scholar
• Arnheim-DahlströmLPasternakBSvanströmHSparénPHviidAAutoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort studyBMJ2013347f590624108159
   PubMed Web of Science ®Google Scholar
• Grimaldi-BensoudaLGuillemotDGodeauBAutoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjectsJ Intern Med2014275439840824206418
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGlobal Advisory Committee on Vaccine Safety, 11–12 December 2013: Human papillomavirus vaccines safety (HPV)Wkly Epidemiol Rec20148975860
   Google Scholar
• European Medicines AgencyPRAC recommendations on signals: Adopted at the PRAC meeting of 7–10 April 2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/04/WC500165809.pdfAccessed September 29, 2014
   Google Scholar
• World Health OrganizationGlobal Advisory Committee on Vaccine Safety, 12–13 June 2013: Update on human papillomavirus vaccinesWkly Epidemiol Rec20138829309312
   Google Scholar
• DennyLSafety of HPV vaccination: a FIGO statementInt J Gynaecol Obstet2013123318718824139200
   PubMed Web of Science ®Google Scholar
• JouraEAKjaerSKWheelerCMHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineVaccine200826526844685118930097
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCHMP variation assessment report: Gardasil2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000703/WC500170695.pdfAccessed April 25, 2014
   Google Scholar
• JouraEEfficacy and immunogenicity of a novel 9-valent HPV l1 virus-like particle vaccine in 16- to 26-year-old womenPoster presented at: Eurogin 2013: HPV at a Crossroads – 30 Years of Research and PracticeNovember 3–6, 2013Florence, Italy
   Google Scholar
• ViscidiRPSnyderBCu-UvinSHuman papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative womenCancer Epidemiol Biomarkers Prev200514128328815668510
   PubMed Web of Science ®Google Scholar
• EklundCUngerERNardelli-HaefligerDZhouTDillnerJInternational collaborative proficiency study of human papillomavirus type 16 serologyVaccine201230229429922079074
   PubMed Web of Science ®Google Scholar
• FergusonMWilkinsonDEZhouTWHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24–25 January 2008, Geneva, SwitzerlandVaccine200927333734719007840
   PubMed Web of Science ®Google Scholar